| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/24/2005 | US6897236 Aminobenzophenones as inhibitors of IL-1β and TNF-α |
| 05/24/2005 | US6897235 Compositions useful for the treatment of pathologies responding to the activation of PPAR-γ receptor |
| 05/24/2005 | US6897233 Enzyme inhibitors, a 2-oxopyrrolidin-3-yl-N-hydroxyacetamide derivatives; bactericides |
| 05/24/2005 | US6897232 Activate soluble guanylate cyclase; for use treating cardiovascular disorders, erectile dysfunction, diabetes, and cirrhosis of the liver, kidney disorders, and learning disability |
| 05/24/2005 | US6897231 Jun n- terminal kinase inhibitors such as 3-(4-methoxyphenyl)-1H-indazole |
| 05/24/2005 | US6897230 Bicyclo[3/1/0] hexane containing oxazolidinone antibiotics and derivatives thereof |
| 05/24/2005 | US6897229 Use of PDE4 inhibitor N-(3,5-dichloropyrid-4-yl)-3-cyclopropylmethoxy-4-difluoromethoxybenzamide, salts or its N-oxide with PDE3 inhibitor for treatment of obstructions of bronchi |
| 05/24/2005 | US6897227 Prodrugs of proton pump inhibitors |
| 05/24/2005 | US6897226 NK-1 receptor active amine oxide prodrugs |
| 05/24/2005 | US6897224 Quinoline and isoquinoline derivatives, a process for their production and their use as inflammation inhibitors |
| 05/24/2005 | US6897222 Pyrido[2,1-a]isoquinoline derivatives |
| 05/24/2005 | US6897221 Urea substituted imidazoquinolines |
| 05/24/2005 | US6897220 Antiproliferative agents |
| 05/24/2005 | US6897219 Central nervous system diosrders; analgesics; antiinflammatory agents |
| 05/24/2005 | US6897218 Nitric oxide donors based on metallic centers |
| 05/24/2005 | US6897216 Adenosine A2a receptor antagonists |
| 05/24/2005 | US6897215 6-(6,5-Bicyclopiperazinyl)-1-(1- naphthylenesulphonyl)indole, for treating schizophrenia, depression, cognition and memory dysfunction, attention deficit disorder |
| 05/24/2005 | US6897212 Treatment of oppositional defiant disorder and conduct disorder with 5-aminoalkyl-4,5,6,7-tetrahydro-4-oxyindolones |
| 05/24/2005 | US6897211 Thienodibenzoazulene compounds as tumor necrosis factor inhibitors |
| 05/24/2005 | US6897210 Anticancer agents; antiarthritic agents |
| 05/24/2005 | US6897207 Kinase inhibitors; angiogenesis inhibitors, anticancer agents, antiinflammatory agents and chronic obstructive pulmonary disease inhibitors |
| 05/24/2005 | US6897206 Combinations for the treatment of inflammatory disorders |
| 05/24/2005 | US6897205 Multi-particulate form of medicament, comprising at least two differently coated forms of pellet |
| 05/24/2005 | US6897203 Polysaccharidic esters of retinoic acid |
| 05/24/2005 | US6897201 Administering a nucleoside 5'-pyrophosphate pyranoside or analogue, of given formula |
| 05/24/2005 | US6897200 Drug delivery a macromolecular complexes containing antitumor agent conjugated with a viral and non-viral RNA or vectors; stable, nonhydrolysis, gene therapy |
| 05/24/2005 | US6897198 Method of treatment with combinations of statin and aryl-substituted propanolamine derivatives |
| 05/24/2005 | US6897196 pH sensitive lipids based on ortho ester linkers, composition and method |
| 05/24/2005 | US6897054 For controlling in vitro cell proliferation; genetic engineering |
| 05/24/2005 | US6897045 Adeno-associated virus vectors |
| 05/24/2005 | US6897034 Antitumor agents; drug immobilized to oligopeptide; complexing; testing, calibration of complex to see if capable of being split enzyme; drug design |
| 05/24/2005 | US6896965 Stents comprising protective coating including interpenetrating polymer network of acrylic acid-ethylene glycol copolymer; drug |
| 05/24/2005 | US6896914 Method for normalizing insulin levels |
| 05/24/2005 | US6896902 Effervescent solid composition of matter |
| 05/24/2005 | US6896901 Controlling or preventing cognitive dysfunction, hyperglycemia and some infective conditions of the skin in mammals by administering pharmaceutically acceptable effective amount of gugulipid |
| 05/24/2005 | US6896900 β-L-2'-deoxy-nucleosides for the treatment of HIV infection |
| 05/24/2005 | US6896899 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 05/24/2005 | US6896898 Analgesics; antiinflammatory agents; sustained release |
| 05/24/2005 | US6896897 For cosmetic and over-the-counter drug applications |
| 05/24/2005 | US6896891 Non-systemic control of parasites |
| 05/24/2005 | US6896888 Comprises Bacillus Calmette-Guerin (BCG) formulated with keratolytic agent (salicyclic acid) for topical application |
| 05/24/2005 | US6896885 Combined use of anti-cytokine antibodies or antagonists and anti-CD20 for treatment of B cell lymphoma |
| 05/24/2005 | US6896877 Crosslinked film forming polymer |
| 05/24/2005 | US6896871 For therapy of soft tissues surrounding bone and bone-related diseases, such as bone cancer and osteoporosis |
| 05/24/2005 | US6895657 For recording and/or reproducing signals on or from a recording medium |
| 05/24/2005 | CA2432405C Water-free skin care formulations comprising micronized urea and method of manufacturing the same |
| 05/24/2005 | CA2359031C Thiazolidinone or oxazolidinone derivatives for treatment of ulcerative disease |
| 05/24/2005 | CA2354237C A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder (adhd) |
| 05/24/2005 | CA2326076C Novel macrolides |
| 05/24/2005 | CA2324306C Polyethoxylated ascorbic acid derivatives as a novel antioxidant and process for preparing thereof |
| 05/24/2005 | CA2315408C A double capsule for the administration of active principles in multiple therapies |
| 05/24/2005 | CA2253785C Sunscreen compositions containing damaged rna fragments |
| 05/24/2005 | CA2240161C Antifungal compositions with improved bioavailability |
| 05/24/2005 | CA2211177C Agent for acting upon bone formation disturbances containing alkaline citrates, lactates and/or malates |
| 05/24/2005 | CA2210708C Tricyclic vasopressin antagonists |
| 05/24/2005 | CA2195615C A process for the manufacture of imidazodiazepine derivatives |
| 05/24/2005 | CA2157792C N-(3-piperidinyl-carbonyl)-beta-alanine derivatives as paf antagonists |
| 05/24/2005 | CA2155840C Hydroxymethyl furazane carboxylic acid derivatives and their use in the treatment of cardio-vascular conditions |
| 05/24/2005 | CA2151476C Use of cyclooxygenase inhibitors for the manufacture of a medicament for enhancing uterine blood perfusion |
| 05/24/2005 | CA2133144C Vitamin d3-analogs |
| 05/24/2005 | CA2132847C Mixed ligand metal complexes of nitric oxide-nucleophile adducts useful as cardiovascular agents |
| 05/24/2005 | CA2109259C Prodrugs, their preparation and use as pharmaceuticals |
| 05/21/2005 | CA2488066A1 Treatment of spondylarthropathies |
| 05/20/2005 | CA2487657A1 Specific markers for metabolic syndrome |
| 05/19/2005 | WO2005045055A2 The use of plp with peg-rmetase in vivo for enhanced efficacy |
| 05/19/2005 | WO2005044988A2 21-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| 05/19/2005 | WO2005044881A1 Carrier for nucleic acid molecule delivery |
| 05/19/2005 | WO2005044874A1 Method of manufacture of polyacrolein |
| 05/19/2005 | WO2005044837A1 The conjugates of a hydrophilic polymer-buxus's extracts and the pharmaceutical compositions of thereof |
| 05/19/2005 | WO2005044834A1 A stabilized azithromycin composition |
| 05/19/2005 | WO2005044823A2 Polymorphous forms of rifaximin as antibiotics |
| 05/19/2005 | WO2005044822A1 Bicyclic pyrazolyl and imidazolyl compounds and uses thereof |
| 05/19/2005 | WO2005044818A2 Imidazo[1,2-a]pyridine anxiolytics |
| 05/19/2005 | WO2005044817A1 Modulators of cellular adhesion |
| 05/19/2005 | WO2005044816A1 Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof |
| 05/19/2005 | WO2005044814A1 BENZO [b][1,4] DIOXEPINE DERIVATIVES |
| 05/19/2005 | WO2005044807A2 Benzoimidazole compounds |
| 05/19/2005 | WO2005044801A1 Pyridine carboxylic acid derivatives as glucokinase modulators |
| 05/19/2005 | WO2005044787A1 Phenetanolamine derivatives |
| 05/19/2005 | WO2005044786A1 Bicyclic amide, carbamate or urea derivatives as vanilloid receptor modulators |
| 05/19/2005 | WO2005044302A1 Selective erbb2 inhibitor/anti-erbb antibody combinations in the treatment of cancer |
| 05/19/2005 | WO2005044299A1 Cytoprotective effects of ethyl pyruvate |
| 05/19/2005 | WO2005044298A1 Compositions and methods of treatment |
| 05/19/2005 | WO2005044290A1 Glucose absorption inhibitor and process for producing the same |
| 05/19/2005 | WO2005044285A1 Anti-adhesion agent with gas bubble |
| 05/19/2005 | WO2005044284A1 Compositions and uses therof |
| 05/19/2005 | WO2005044283A1 Allergic constitution ameliorator |
| 05/19/2005 | WO2005044282A1 Use of nucleic acids comprising an exocyclic adduct |
| 05/19/2005 | WO2005044281A1 Baicalin and its derivatives as a treatment for sars corona virus infection or other related infections |
| 05/19/2005 | WO2005044280A1 Biphosphonate pharmaceutical formulations (water emulsion of lipids/phospholipids) and use thereof |
| 05/19/2005 | WO2005044279A1 Purine nucleoside phosphonate conjugates |
| 05/19/2005 | WO2005044278A1 Myo-inositol hexaphosphate for topical use |
| 05/19/2005 | WO2005044277A1 Protein tyrosine phosphatase 1b (ptp-1b) inhibitors and methods of using the same |
| 05/19/2005 | WO2005044276A1 Pharmaceutical composition containing prostaglandin |
| 05/19/2005 | WO2005044275A1 Use |
| 05/19/2005 | WO2005044274A1 Roscovitine treatment of mantle cell lymphoma |
| 05/19/2005 | WO2005044273A1 Controlled release delivery system for nasal applications |
| 05/19/2005 | WO2005044272A1 Compositions and methods for treating cellular proliferation disorders |
| 05/19/2005 | WO2005044271A1 Pharmaceutical formulations containing flavouring substances with improved pharmaceutical properties |
| 05/19/2005 | WO2005044270A1 Oxadiazolopyrazine derivatives as pharmaceutically active compounds |